Literature DB >> 12602423

Treatment of generalized anxiety disorder in older adults.

Julie Loebach Wetherell1, Margaret Gatz, Michelle G Craske.   

Abstract

Older adults with generalized anxiety disorder (GAD; N = 75; M age = 67.1 years) were randomly assigned to cognitive-behavioral therapy (CBT), a discussion group (DG) organized around worry-provoking topics, or a waiting period. Participants in both active conditions improved relative to the waiting list. Although CBT participants improved on more measures than DG participants, the authors found only I significant difference immediately after treatment and no differences at 6-month follow-up. Effect sizes were smaller than in younger samples, but CBT showed large effects and DG showed medium-sized effects Overall, results indicate that brief treatment of late-life GAD is beneficial, but they provide only limited support for the superiority of CBT to a credible comparison intervention.

Entities:  

Mesh:

Year:  2003        PMID: 12602423     DOI: 10.1037//0022-006x.71.1.31

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  57 in total

1.  Enabling lay providers to conduct CBT for older adults: key steps for expanding treatment capacity.

Authors:  Cynthia Kraus-Schuman; Nancy L Wilson; Amber B Amspoker; Paula D Wagener; Jessica S Calleo; Gretchen Diefenbach; Derek Hopko; Jeffrey A Cully; Ellen Teng; Howard M Rhoades; Mark E Kunik; Melinda A Stanley
Journal:  Transl Behav Med       Date:  2015-09       Impact factor: 3.046

Review 2.  Psychological therapies for generalised anxiety disorder.

Authors:  V Hunot; R Churchill; M Silva de Lima; V Teixeira
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Treatment of comorbid anxiety and autism spectrum disorders.

Authors:  Joshua Nadeau; Michael L Sulkowski; Danielle Ung; Jeffrey J Wood; Adam B Lewin; Tanya K Murphy; Jill Ehrenreich May; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2011-12

4.  Emotion Reactivity and Cerebrovascular Burden in Late-Life GAD: A Neuroimaging Study.

Authors:  Helmet Karim; Dana Larisa Tudorascu; Howard Aizenstein; Sarah Walker; Rachel Good; Carmen Andreescu
Journal:  Am J Geriatr Psychiatry       Date:  2016-07-21       Impact factor: 4.105

5.  Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.

Authors:  Emily Carl; Sara M Witcraft; Brooke Y Kauffman; Eilis M Gillespie; Eni S Becker; Pim Cuijpers; Michael Van Ameringen; Jasper A J Smits; Mark B Powers
Journal:  Cogn Behav Ther       Date:  2019-02-14

6.  Predictors of change in quality of life in older adults with generalized anxiety disorder.

Authors:  Srijana Shrestha; Melinda A Stanley; Nancy L Wilson; Jeffrey A Cully; Mark E Kunik; Diane M Novy; Howard M Rhoades; Amber B Amspoker
Journal:  Int Psychogeriatr       Date:  2014-12-12       Impact factor: 3.878

7.  Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment.

Authors:  Carmen Andreescu; Lei K Sheu; Dana Tudorascu; James J Gross; Sarah Walker; Layla Banihashemi; Howard Aizenstein
Journal:  Am J Geriatr Psychiatry       Date:  2014-05-17       Impact factor: 4.105

8.  Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial.

Authors:  Melinda A Stanley; Nancy L Wilson; Diane M Novy; Howard M Rhoades; Paula D Wagener; Anthony J Greisinger; Jeffrey A Cully; Mark E Kunik
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

9.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

Review 10.  Current status of psychotherapy for mental disorders in the elderly.

Authors:  Amber Gum; Patricia A Areán
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.